An interventional study of Antiplatelet treatment discontinuation in Patent Foramen Ovale, Ischemic Stroke and Bleeding Ulcer, sponsored by Josep Rodes-Cabau. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Josep Rodes-Cabau · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Foramen Ovale, Patent with a site in Canada — 6 open to participants now, 9 under way, none of them phase 3. Foramen Ovale, Patent · Canada.
Among the 14 studies in Foramen Ovale, Patent with a site in Canada, this one is one of 2 that started in 2020, is one of 7 with no phase, and was the 7th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →6 of the 14 studies in Foramen Ovale, Patent with a site in Canada are open now. Recruiting first, the newest first:
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Josep Rodes-Cabau · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–110
Luciano A. Sposato · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–110
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2020.
This study's planned enrollment of 100 is below the median of 154 across 69 interventional studies indexed under Foramen Ovale, Patent.
Median enrollment 601 across the 8 interventional studies, 495 across the 6 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 8 most frequent:
Josep Rodes-Cabau is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Josep Rodes-Cabau has 2 studies filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
2 of the studies in Foramen Ovale, Patent with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04475510Josep Rodes-CabauDiscontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke | 2027-06-01 |
| NCT05907694Josep Rodes-CabauMedical Treatment With or Without Transcatheter Patent Foramen Ovale Closure | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Foramen Ovale, Patent with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.
Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
->60 year-old
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
Other: Antiplatelet treatment discontinuation
All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
Presence of new stroke events
1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR \< 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death.
Time frame: 12 months
Presence of new ischemic lesions
Evaluated by MRI
Time frame: 24-month follow-up
Number of new cerebral ischemic lesions
Evaluated by MRI
Time frame: 24-month follow-up
Volume of new cerebral ischemic lesions
Evaluated by MRI
Time frame: 24-month follow-up
Number of ischemic events
Stroke, TIA
Time frame: 24-month follow-up
Number of ischemic events
Stroke, TIA
Time frame: 3-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 4-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 5-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 6-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 7-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 8-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 9-year follow-up
Number of ischemic events
Stroke, TIA
Time frame: 10-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 24-month follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 3-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 4-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 5-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 6-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 7-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 8-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 9-year follow-up
Rate of bleeding
Life-threatening, major or minor bleeding
Time frame: 10-year follow-up
Started Jul 2020 (actual). Primary completion is estimated for Jun 2027, 82 months after the start.
Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 82 months is above that.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Josep Rodes-Cabau